Shire plc has acquired New York-based Foresight Biotherapeutics Inc. for $300 million in cash, gaining the global rights to FST-100 topical ophthalmic drops in late-stage development for the treatment of infectious conjunctivitis. The acquisition expands Shire’s late-stage ophthalmic pipeline that includes lifitegrast, which is in late-stage development for treatment of dry eye disease. If approved, FST-100 has the potential to become the first agent to treat both viral and bacterial conju...